Themis Medicare Limited · NSE:THEMISMED
Themis Medicare — Q1 FY25 Earnings Presentation
18 slides from Themis Medicare's earnings presentation, Jul 27, 2024
Slide 1: Cover letter to stock exchanges: Investor Presentation
TML: CS: BSE/NSE CORR: 2024-25 26th July, 2024 Listing Department, Listing Department, BSE Limited, National Stock Exchange of India Ltd. P. J. Towers, Dalal Street, “Exchange Plaza”, Mumbai-400001 Bandra – Kurla Complex, BSE Scrip Code: 530199 Bandra – East, Mumbai- 400 051 NSE Scrip Code: THEMISME
Slide 2: Themis Medicare Ltd. Result Update Presentation Q1 FY25
In every possibility lies an innate, latent power to change lives Themis Medicare Ltd. Result Update Presentation Q1 FY25
Slide 3: Disclaimer
Disclaimer This presentation has been prepared by Themis Medicare Limited (the “Company” or “Themis” or “TML”) solely for information purposes and does not constitute any offer, recommendation or invitation to purchase or subscribe for any securities, and shall not form the basis or be relied on in
Slide 4: Table of Contents
Table of Contents Consolidated Financial Highlights Company Overview Way Ahead 3
Slide 5: Consolidated Financial Highlights
Consolidated Financial Highlights
Slide 6: Management Comment
Management Comment Commenting on the result, Dr. Sachin Patel, Managing Director & CEO, said: “I am pleased to inform you that the Q1FY25 results reflect the efficient execution of our strategic plans which have been developed and implemented by the Company in the past few quarters, especially in th
Slide 7: Consolidated Quarterly Financial Highlights
Consolidated Quarterly Financial Highlights Revenue (Rs. Cr.)* EBITDA (Rs. Cr.)** / Margin (%) 123.0 30 23.7% 22.5% 25% 104.8 96.7 97.8 25 29.2 20% 82.5 20 21.7 11.8% 15% 15 9.8% 9.5% 10% 10 5 12.4 9.3 5% 8.1 0 0% Q1 FY24 Q2 FY24 Q3 FY24 Q4 FY24 Q1 FY25 Q1FY24 Q2FY24 Q3FY24 Q4FY24 Q1 FY25 PAT (Rs. C
Slide 8: Consolidated Quarterly Financial Highlights – Q1 FY25
Consolidated Quarterly Financial Highlights – Q1 FY25 Particulars (Rs. Cr.) Q1 FY25 Q1 FY24 Y-o-Y (%) Q4 FY24 Net Revenue 122.99 96.65 27.26% 97.82 • Formulation Segment has grown by Cost of Material Consumed 23.52 15.71 21.65 ~53% year-on-year for Q1FY25 Purchase of SIT 16.74 9.79 11.79 Changes in
Slide 9: Consolidated Full Year Financial Highlights – FY24
Consolidated Full Year Financial Highlights – FY24 Particulars (Rs. Cr.) FY24 FY23 Y-o-Y (%) Net Revenue 381.76 354.32 7.74% Cost of Material Consumed 84.67 96.04 Purchase of SIT 53.61 30.12 Changes in Inventory (1.57) (7.79) Employee Expenses 82.41 66.15 Other Expenses 111.13 102.36 Total Expenditu
Slide 10: Company Overview
Company Overview
Slide 11: Snapshot of Company
Snapshot of Company Strategic focus To become Leader in Hospital Business in India with 4 Strong Balance Sheet growing divisions contributing 38% to revenue Total Debt to Equity at 0.25 in FY23-24 3 State of art manufacturing facilities in India – Rs. 1,937 Cr 1 Formulations and 2 APIs (Synthetic +
Slide 12: Strong Business Model
Strong Business Model 01 Businesswise Revenue – Q1 FY24-25 Hospital Hospital Business 33% is major growth 03 API, Co. driver Mkt & Others 50% Trade 17% n 02 n Hospital Business API Business Critical Care Division API Legacy Business Intensive Care Division New Product pipeline Businesswise R
Slide 13: Vertically Integrated State of Art Manufacturing Capabilities
Vertically Integrated State of Art Manufacturing Capabilities Location Particulars Haridwar Hyderabad Vapi Artemis Biotech Themis Medicare Ltd. Themis Medicare Ltd. (Division of Themis Medicare Ltd.) Segment Formulations Synthetic APIs Synthetic APIs Tablets (Nos.) - 520 mn Ointment (No. of Tubes) -
Slide 14: Strong Research and Development Capabilities
Strong Research and Development Capabilities Continued Investment in R&D (Rs. Cr.) Business API Formulations 14.25 13.64 13.69 R&D 12 7 Analytical Lab 8.50 9 7 Development 4.59 Product in a year with 3.43 5–8 20-24 documentation FY18-19 FY19-20 FY20-21 FY21-22 FY22-23 FY23-24 Products in work rollin
Slide 15: Way Ahead
Way Ahead
Slide 16: Hospital Business Opportunity
n Hospital Business Opportunity Why Hospital Business Segment? Growing market - Themis has strong foot in door through Critical Care Market Highly Fragmented unlike West where 3-4 players control 90% market share Opportunities to grow segments within HB High Entry Barriers Large Product Port
Slide 17: Our Aspirations
Our Aspirations Vision & Position Provide hospitals and health systems ‘The Best Experience Leader business model” to ensure customer satisfaction Leadership in Anesthesia and Critical Care Strategy Focus on Hospital business APIs to be developed - in-house New Target Markets consumption and
Slide 18: Thank You
Thank You It takes one word to change the world “POSSIBILITY” For further information, please contact: Mr. Sangameshwar Iyer Mr. Amit Sharma / Ms. Disha Shah Tel: +91 9867726686 / 9699060134 Themis Medicare Ltd Adfactors PR Pvt Ltd Email: sangameshwar.iyer@themismedicare.com Email: amit.sharma@adfac